SCHEMBL2980946

SCHEMBL2980946

Cc1ccc2c3c([nH]c2c1)CNCC3

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 3/20 0.67
ADRA2A P08913 1/20 0.67
ADRA2B P18089 1/20 0.67
ADRA2C P18825 1/20 0.67
HTR7 P34969 1/20 0.67
KDM4E B2RXH2 2/20 0.61
HTR5A P47898 1/20 0.61
NR2E1 Q9Y466 1/20 0.61
LMNA P02545 2/20 0.55
HSD17B10 Q99714 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2D6 P10635 1/20 0.55
THRB P10828 1/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
NFKB1 P19838 1/20 0.55
RECQL P46063 1/20 0.55
PMP22 Q01453 1/20 0.55
SIRT2 Q8IXJ6 1/20 0.47
HTR2A P28223 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25512897 0.89 HTR2A (0.60) NISCHADRA2AADRA2BADRA2CHTR7
SCHEMBL7818620 0.87 LMNA (0.67) NISCHADRA2AADRA2BADRA2CHTR7
SCHEMBL4126722 0.87 SIRT2 (0.60) NISCHADRA2AADRA2BADRA2CHTR7
SCHEMBL31020972 0.87 SIRT2 (0.60) NISCHADRA2AADRA2BADRA2CHTR7
Hydrochloric Acid SCHEMBL23828316 0.86 TAAR1 (0.62) NISCHADRA2AADRA2BADRA2CHTR7
Hydrochloric Acid SCHEMBL9615100 0.86 LMNA (0.65) NISCHADRA2AADRA2BADRA2CHTR7
Hydrochloric Acid SCHEMBL31020957 0.86 TAAR1 (0.62) NISCHADRA2AADRA2BADRA2CHTR7
SCHEMBL14757840 0.82 NISCH (0.64) NISCHADRA2AADRA2BADRA2CHTR7
SCHEMBL20883912 0.81 NISCH (0.63) NISCHADRA2AADRA2BADRA2CHTR7
SCHEMBL12369408 0.81 NISCH (0.62) NISCHADRA2AADRA2BADRA2CHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019074979-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF GIRAFPHARMA, LLC (US) 2019-04-18 WO disclosed
US-7772245-B2 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. (US) 2010-08-10 US disclosed
US-20060199829-A1 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. 2006-09-07 US disclosed
EP-0705832-B1 Serotonergic modulators LILLY CO ELI (GB) 2003-08-13 EP disclosed
US-5563147-A CENTRAL NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY (US) 1996-10-08 US disclosed
EP-0705832-A1 Serotonergic modulators LILLY INDUSTRIES LIMITED (GB) 1996-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199829-A1 Inhibitors of histone deacetylase HDAC1, HDAC2, HDAC11 NISCH 4666/4885ADRA2A 2604/4885ADRA2B 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.